We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

News & Events

Spark Therapeutics, Inc. has announced the initiation of a phase 1/2 trial of SPK-8011, the company’s investigational gene transfer candidate for hemophilia A.  

Statement from Genentech/Roche on HAVEN 1 Clinical Trial

A statement from Genentech/Roche regarding the death of a participant in the HAVEN 1 clinical trial.

Be Prepared for Washington Days

Coming to Washington Days? Learn what to expect and how to make the most out of your experience with NHF's 1 hour webinar.

The Partners in Bleeding Disorders Education Program has relaunched an ethics-related educational activity for healthcare providers at hemophilia treatment centers (HTCs).

AbbVie recently announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for glecaprevir/pibrentasvir (G/P). G/P is the company’s investigational combination therapy regimen for the treatment of all major genotypes of the chronic hepatitis C virus (HCV). The once-daily, orally-administered therapy includes two distinct antiviral agents in a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor.

View Archives


Fill in the fields below to receive our email newsletter.